New Liver Tissue Technique Reduces Need for Liver Transplants

A new study published in the journal Science Advances has demonstrated a technique for growing small, functional liver tissues inside the body using engineered cell implants that grow in a controlled manner, potentially reducing the need for full liver transplants in patients with advanced liver disease.

The research, conducted by scientists at the Massachusetts Institute of Technology (MIT) and Harvard Medical School, involves implanting bioengineered liver tissue precursors — termed “BOOST” (Biologically Optimized Organoid-Supported Tissues) — into mouse models of liver injury. These tissues are designed to respond to the body’s own regenerative signals, growing only to the size and functional capacity needed to compensate for damaged liver tissue, without overgrowth or tumor formation.

Unlike traditional organoid transplantation approaches, which often require pre-formed mini-organs grown outside the body, the BOOST method uses programmable synthetic biology circuits to regulate tissue growth in vivo. The implanted cells contain genetic switches that activate proliferation in response to elevated levels of specific biomarkers associated with liver damage, such as increased bilirubin or decreased albumin production, and halt growth once tissue mass reaches a therapeutic threshold.

In the study, mice with chemically induced liver fibrosis showed significant improvement in liver function after BOOST implantation. Measurements of serum liver enzymes, bilirubin clearance, and albumin synthesis returned to near-normal levels within eight weeks. Histological analysis confirmed that the implanted tissues integrated with the host liver vasculature and performed key metabolic functions, including drug detoxification and protein synthesis, without inducing immune rejection or abnormal proliferation.

“This approach shifts the paradigm from replacing the entire organ to augmenting the liver’s intrinsic repair capacity,” said Dr. Sangeeta Bhatia, senior author of the study and a professor at MIT’s Institute for Medical Engineering and Science. “By engineering cells to sense the liver’s needs and respond with precise, self-limiting growth, we aim to provide a scalable alternative to transplantation, especially for patients who are not eligible for donor organs due to comorbidities or organ shortages.”

The BOOST platform builds on advances in synthetic biology and tissue engineering, particularly the use of ligand-inducible genetic controllers that allow external or internal cues to modulate gene expression. In this case, the circuit is designed to be activated only by pathophysiological signals present in diseased liver microenvironments, minimizing off-target effects in healthy tissue.

Liver disease remains a leading cause of mortality worldwide, with conditions such as cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) driving demand for transplants that far exceeds supply. According to the World Health Organization, over 2 million deaths annually are attributable to liver disease, and fewer than 10% of patients in need receive a transplant due to donor scarcity and surgical risks.

While the results are promising, researchers caution that the technology is still in preclinical stages. Key challenges include scaling the technique to larger animal models, ensuring long-term stability and function of the implanted tissues beyond several months, and verifying safety in immunocompromised or chronically inflamed environments typical of advanced liver disease.

The team plans to next test BOOST in porcine models, which more closely mimic human liver anatomy and physiology, followed by discussions with regulatory agencies about potential pathways for human trials. If successful, the approach could eventually be adapted for other organs with regenerative capacity, such as the kidney or pancreas.

Experts not involved in the study have noted the innovation’s potential but emphasized the need for rigorous safety monitoring. “The ability to control tissue growth dynamically is a significant step forward,” said Dr. Luiz Bertassoni, a bioengineer at Columbia University not affiliated with the research. “But as with any living therapeutic, we must ensure that these engineered constructs do not evolve unpredictably over time — long-term studies will be essential.”

The study was funded by the National Institutes of Health (NIH), the Howard Hughes Medical Institute, and the Koch Institute for Integrative Cancer Research at MIT. No conflicts of interest were reported by the authors.